Compare State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF (SJNK) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF vs Zoetis Inc — how do they compare? State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF trades at $24.87, while Zoetis Inc trades at $73.88 (market cap $31.14B). The key difference: Zoetis Inc pays a 2.81% dividend while State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF pays none, and State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF is trading nearer its 52-week high, Zoetis Inc nearer its low. Which is the better fit depends on your goals.
| SJNK | ZTS | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $25.63 | $156.76 |
52-Week Low | $24.75 | $71.91 |
Market Cap | — | $31.14B |
Enterprise Value | — | $38.70B |
Dividend Yield | — | 2.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SJNK trades at $24.87, up 0.16% on the day, with a bearish technical signal from moving averages and neutral oscillators. The ETF shows consistent dividend distributions, with recent payouts of $0.14-$0.15. Institutional activity includes Cetera Investment Advisers reducing its position by 9.4% as of July 28, 2026, while news sentiment reflects caution on high-yield bonds.
The outlook remains cautious due to technical bearishness and negative media coverage, with risks from interest rate sensitivity and credit spreads. Investment appeal hinges on yield stability, but macroeconomic headwinds could pressure performance. Analysts highlight correlated vulnerabilities with broader junk bond ETFs.
Zoetis (ZTS) trades at $73.4, down 1.95% on the day, as technical indicators signal a bearish trend amid recent price weakness. Fundamentally, the company reported Q2 2026 EPS of $1.87, beating estimates, but revenue was flat and full-year guidance was cut due to softer pet healthcare demand. Analyst sentiment remains mixed with a consensus price target of $94.90, though recent news highlights competitive pressures and a securities class action lawsuit.
The stock presents a value opportunity given its attractive P/E of 12.29 and strong profitability margins, but near-term headwinds from U.S. companion-animal market challenges and legal overhangs pose risks. Upside depends on execution against revised 2026 targets and stabilization in core markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF
SJNK invests in U.S. dollar-denominated high-yield corporate bonds with short-term maturities (under five years). It offers higher yields than investment-grade funds but with less interest rate sensitivity than longer-term junk bond ETFs.
Read more on SJNK →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
